238 Publications, 217 referenced in PubMed  (PubMed links, other articles marked in blue) 

 

12720 checked citations, 33 with at least 100 citations, mean 50 citations/article  *   h-index: * 64 * July 13, 2023 *

 


238. Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies.

Devaux CA, Fantini J.Pathogens. 2023 May 13;12(5):713.

 

237. Lipid rafts and human diseases: why we need to target gangliosides.

Fantini J.FEBS Open Bio. 2023 Apr 13. doi: 10.1002/2211-5463.13612. Online ahead of print.PMID: 37052878 

 

236. lectrostatic Surface Potential as a Key Parameter in Virus Transmission and Evolution: How to Manage Future Virus Pandemics in the Post-COVID-19 Era.

Fantini J, Azzaz F, Chahinian H, Yahi N.Viruses. 2023 Jan 19;15(2):284. doi: 10.3390/v15020284.

 

235. Convergent Evolution Dynamics of SARS-CoV-2 and HIV Surface Envelope Glycoproteins Driven by Host Cell Surface Receptors and Lipid Rafts: Lessons for the Future.

Fantini J, Chahinian H, Yahi N.Int J Mol Sci. 2023 Jan 18;24(3):1923. doi: 10.3390/ijms24031923.

 

234. Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors.

Azzaz F, Hilaire D, Fantini J.Chem Biol Interact. 2023 Mar 1;373:110384. doi: 10.1016/j.cbi.2023.110384.

 

233. AmyP53 Prevents the Formation of Neurotoxic β-Amyloid Oligomers through an Unprecedent Mechanism of Interaction with Gangliosides: Insights for Alzheimer's Disease Therapy.

Azzaz F, Chahinian H, Yahi N, Fantini J, Di Scala C.Int J Mol Sci. 2023 Jan 16;24(2):1760. doi: 10.3390/ijms24021760.

 

232. SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects.

Boschi C, Scheim DE, Bancod A, Militello M, Bideau ML, Colson P, Fantini J, Scola B.Int J Mol Sci. 2022 Dec 7;23(24):15480. doi: 10.3390/ijms232415480.

 

231. Structural Basis of Botulinum Toxin Type F Binding to Glycosylated Human SV2A: In Silico Studies at the Periphery of a Lipid Raft.

Azzaz F, Hilaire D, Fantini J.Biomolecules. 2022 Dec 6;12(12):1821. doi: 10.3390/biom12121821.

 

230. A Vaccine Strategy Based on the Identification of an Annular Ganglioside Binding Motif in Monkeypox Virus Protein E8L.

Fantini J, Chahinian H, Yahi N.Viruses. 2022 Nov 16;14(11):2531. doi: 10.3390/v14112531.

 

229. AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer's and Parkinson's Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery.

Di Scala C, Armstrong N, Chahinian H, Chabrière E, Fantini J, Yahi N.Int J Mol Sci. 2022 Nov 2;23(21):13383. doi: 10.3390/ijms232113383.

 

228. First Detection of the SARS-CoV-2 Omicron BA.5/22B in Monaco.

Colson P, Lavagna C, Delerce J, Groshenry G, Yahi N, Fantini J, La Scola B, Althaus T.Microorganisms. 2022 Sep 30;10(10):1952. doi: 10.3390/microorganisms10101952.

 

227. The Epigenetic Dimension of Protein Structure Is an Intrinsic Weakness of the AlphaFold Program.

Azzaz F, Yahi N, Chahinian H, Fantini J.Biomolecules. 2022 Oct 20;12(10):1527. doi: 10.3390/biom12101527.

 

226. Role of spike compensatory mutations in the interspecies transmission of SARS-CoV-2.

Frutos R, Yahi N, Gavotte L, Fantini J, Devaux CA.One Health. 2022 Dec;15:100429. doi: 10.1016/j.onehlt.2022.100429. Epub 2022 Aug 29.

 

225. The emergence, spread and vanishing of a French SARS-CoV-2 variant exemplifies the fate of RNA virus epidemics and obeys the Mistigri rule.

Colson P, Gautret P, Delerce J, Chaudet H, Pontarotti P, Forterre P, Tola R, Bedotto M, Delorme L, Bader W, Levasseur A, Lagier JC, Million M, Yahi N, Fantini J, La Scola B, Fournier PE, Raoult D.J Med Virol. 2023 Jan;95(1):e28102.

 

224. Molecular landscape of BoNT/B bound to a membrane-inserted synaptotagmin/ganglioside complex.

Ramirez-Franco J, Azzaz F, Sangiardi M, Ferracci G, Youssouf F, Popoff MR, Seagar M, Lévêque C, Fantini J, El Far O.Cell Mol Life Sci. 2022 Aug 25;79(9):496. doi: 10.1007/s00018-022-04527-4.

 

223. Structural Dynamics of the SARS-CoV-2 Spike Protein: A 2-Year Retrospective Analysis of SARS-CoV-2 Variants (from Alpha to Omicron) Reveals an Early Divergence between Conserved and Variable Epitopes.

Guérin P, Yahi N, Azzaz F, Chahinian H, Sabatier JM, Fantini J.Molecules. 2022 Jun 15;27(12):3851. doi: 10.3390/molecules27123851.

 

222. Culture and identification of a "Deltamicron" SARS-CoV-2 in a three cases cluster in southern France.

Colson P, Fournier PE, Delerce J, Million M, Bedotto M, Houhamdi L, Yahi N, Bayette J, Levasseur A, Fantini J, Raoult D, La Scola B.J Med Virol. 2022 Aug;94(8):3739-3749. doi: 10.1002/jmv.27789. Epub 2022 May 6.

 

221. The novel hamster-adapted SARS-CoV-2 Delta variant may be selectively advantaged in humans.

Fantini J, Devaux CA, Yahi N, Frutos R.J Infect. 2022 May;84(5):e53-e54. doi: 10.1016/j.jinf.2022.03.001.

 

220. First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France.

Colson P, Delerce J, Beye M, Levasseur A, Boschi C, Houhamdi L, Tissot-Dupont H, Yahi N, Million M, La Scola B, Fantini J, Raoult D, Fournier PE.J Med Virol. 2022 Jul;94(7):3421-3430. doi: 10.1002/jmv.27695.

 

219. The epigenetic dimension of protein structure.

Azzaz F, Fantini J.Biomol Concepts. 2022 Feb 21;13(1):55-60. doi: 10.1515/bmc-2022-0006.PMID: 35189052 

 

218. Emergence in southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K substitutions in the spike protein.

Colson P, Delerce J, Burel E, Dahan J, Jouffret A, Fenollar F, Yahi N, Fantini J, La Scola B, Raoult D.Arch Virol. 2022 Apr;167(4):1185-1190. doi: 10.1007/s00705-022-05385-y.

 

217. Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France.

Colson P, Fantini J, Yahi N, Delerce J, Levasseur A, Fournier PE, Lagier JC, Raoult D, La Scola B.Arch Virol. 2022 Feb;167(2):583-589.

 

216. Ganglioside binding domains in proteins: Physiological and pathological mechanisms.

Azzaz F, Yahi N, Di Scala C, Chahinian H, Fantini J.Adv Protein Chem Struct Biol. 2022;128:289-324. doi: 10.1016/bs.apcsb.2021.08.003.

 

215. The puzzling mutational landscape of the SARS-2-variant Omicron.

Fantini J, Yahi N, Colson P, Chahinian H, La Scola B, Raoult D.J Med Virol. 2022 May;94(5):2019-2025. doi: 10.1002/jmv.27577.

 

214. High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2.

Jaafar R, Boschi C, Aherfi S, Bancod A, Le Bideau M, Edouard S, Colson P, Chahinian H, Raoult D, Yahi N, Fantini J, La Scola B.Viruses. 2021 Oct 28;13(11):2177. doi: 10.3390/v13112177.

 

213. Gene Therapy Strategy for Alzheimer's and Parkinson's Diseases Aimed at Preventing the Formation of Neurotoxic Oligomers in SH-SY5Y Cells.

El-Battari A, Rodriguez L, Chahinian H, Delézay O, Fantini J, Yahi N, Di Scala C.Int J Mol Sci. 2021 Oct 26;22(21):11550. doi: 10.3390/ijms222111550.

 

212. Endocannabinoids tune intrinsic excitability in O-LM interneurons by direct modulation of post-synaptic Kv7 channels.Incontro S, Sammari M, Azzaz F, Inglebert Y, Ankri N, Russier M, Fantini J, Debanne D. 
J Neurosci. 2021 Oct 6:JN-RM-1279-21.

211.Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?

Yahi N, Chahinian H, Fantini J.J Infect. 2021 Nov;83(5):607-635. doi: 10.1016/j.jinf.2021.08.010.

 

210. Structural dynamics of SARS-CoV-2 variants: a health monitoring strategy for anticipating Covid-19 outbreaks.

Fantini J, Yahi N, Azzaz F, Chahinian H.

J Infect. 2021 Jun 2:S0163-4453(21)00281-4. 

 

209. Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19.

Fantini J, Chahinian H, Yahi N.Biochem Biophys Res Commun. 2020 Oct 10:S0006-291X(20)31924-0. doi: 10.1016/j.bbrc.2020.10.015.

 

208.  Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers?
Fantini J, Chahinian H, Yahi N.  Protein Sci. 2020 Aug;29(8):1748-1759.

 

207.  Synergistic Antiviral Effect of Hydroxychloroquine and Azithromycin in Combination Against SARS-CoV-2: What Molecular Dynamics Studies of Virus-Host Interactions Reveal. Fantini J, Chahinian H, Yahi N. Int J Antimicrob Agents. 2020 May 13;106020.

 

206. Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Fantini J, Di Scala C, Chahinian H, Yahi N.  Int J Antimicrob Agents. 2020 Apr 3:105960. 

 

205. Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B. Flores A, Ramirez-Franco J, Desplantes R, Debreux K, Ferracci G, Wernert F, Blanchard MP, Maulet Y, Youssouf F, Sangiardi M, Iborra C, Popoff MR, Seagar M, Fantini J, Lévêque C, El Far O.   Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):18098-18108. 

204. Cholesterol-Recognition Motifs in Membrane Proteins. Fantini J, Epand RM, Barrantes FJ. Adv Exp Med Biol. 2019;1135:3-25. 

 

203. The glycosphingolipid MacCer promotes synaptic bouton formation in Drosophila by interacting with Wnt.

Huang Y, Huang S, Di Scala C, Wang Q, Wandall HH, Fantini J, Zhang YQ.  Elife. 2018 Oct 25;7. 

 

202. Anandamide Revisited: How Cholesterol and Ceramides Control Receptor-Dependent and Receptor-Independent Signal Transmission Pathways of a Lipid Neurotransmitter.

Di Scala C, Fantini J, Yahi N, Barrantes FJ, Chahinian H.Biomolecules. 2018 May 22;8(2):31.

  

201. How membrane lipids control the 3D structure and function of proteins. Fantini J, Barrantes FJ. AIMS Biophys. 2018;5:22-35.

 

200. Relevance of CARC and CRAC Cholesterol-Recognition Motifs in the Nicotinic Acetylcholine Receptor and Other Membrane-Bound Receptors. 

Di Scala C, Baier CJ, Evans LS, Williamson PTF, Fantini J, Barrantes FJ. Curr Top Membr. 2017;80:3-23.

 

199. Anandamide-ceramide interactions in a membrane environment: Molecular dynamic simulations data.

Di Scala C, Mazzarino M, Yahi N, Varini K, Garmy N, Fantini J, Chahinian H. Data Brief. 2017 Jul 14;14:163-167.

 

198.Ceramide binding to anandamide increases its half-life and potentiates its cytotoxicity in human neuroblastoma cells.

Di Scala C, Mazzarino M, Yahi N, Varini K, Garmy N, Fantini J, Chahinian H. Chem Phys Lipids. 2017 Jun;205:11-17.

 

197. Hybrid In Silico/In Vitro Approaches for the Identification of Functional Cholesterol-Binding Domains in Membrane Proteins.

Di Scala C, Fantini J. Methods Mol Biol. 2017;1583:7-19. 

 

196.Common molecular mechanism of amyloid pore formation by Alzheimer's β-amyloid peptide and α-synuclein.

Di Scala C, Yahi N, Boutemeur S, Flores A, Rodriguez L, Chahinian H, Fantini J. Sci Rep. 2016 Jun 29;6:28781.

 

195. From hopanoids to cholesterol: Molecular clocks of pentameric ligand-gated ion channels.

Barrantes FJ, Fantini J. Prog Lipid Res. 2016 Jul;63:1-13. 

 

194. Molecular mechanisms of protein-cholesterol interactions in plasma membranes: Functional distinction between topological (tilted) and consensus (CARC/CRAC) domains.

Fantini J, Di Scala C, Baier CJ, Barrantes FJ. Chem Phys Lipids. 2016 Sep;199:52-60. 

 

193. A mirror code for protein-cholesterol interactions in the two leaflets of biological membranes.

Fantini J, Di Scala C, Evans LS, Williamson PT, Barrantes FJ. Sci Rep. 2016 Feb 26;6:21907

 

192. Comparison of the amyloid pore forming properties of rat and human Alzheimer's beta-amyloid peptide 1-42: Calcium imaging data.

Di Scala C, Yahi N, Flores A, Boutemeur S, Kourdougli N, Chahinian H, Fantini J. Data Brief. 2016 Jan 16;6:640-3.

 

191. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides.

Di Scala C, Yahi N, Flores A, Boutemeur S, Kourdougli N, Chahinian H, Fantini J. Biochim Biophys Acta. 2016 Feb;1862(2):213-22.

 

190. Deciphering the glycolipid code of Alzheimer's and Parkinson's amyloid proteins allowed the creation of a universal ganglioside-binding peptide.

Yahi N, Fantini J. PLoS One. 2014 Aug 20;9(8):e104751. 

 

189. A cholesterol recognition motif in human phospholipid scramblase 1.

Posada IM, Fantini J, Contreras FX, Barrantes F, Alonso A, Goñi FM. Biophys J. 2014 Sep 16;107(6):1383-92.

 

188. Interaction of Alzheimer's β-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation.

Di Scala C, Chahinian H, Yahi N, Garmy N, Fantini J. Biochemistry. 2014 Jul 22;53(28):4489-502.

 

187. CH-π hydrogen bonds in biological macromolecules.

Nishio M, Umezawa Y, Fantini J, Weiss MS, Chakrabarti P. Phys Chem Chem Phys. 2014 Jul 7;16(25):12648-83. 

 

186. Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's β-amyloid peptides.

Fantini J, Di Scala C, Yahi N, Troadec JD, Sadelli K, Chahinian H, Garmy N. ACS Chem Neurosci. 2014 Mar 19;5(3):216-24. 

 

185. Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β-amyloid peptide.

Di Scala C, Troadec JD, Lelièvre C, Garmy N, Fantini J, Chahinian H. J Neurochem. 2014 Jan;128(1):186-95. 

 

184. A glycosphingolipid binding domain controls trafficking and activity of the mammalian notch ligand delta-like 1.

Heuss SF, Tarantino N, Fantini J, Ndiaye-Lobry D, Moretti J, Israël A, Logeat F. PLoS One. 2013 Sep 12;8(9):e74392.

 

183. The driving force of alpha-synuclein insertion and amyloid channel formation in the plasma membrane of neural cells: key role of ganglioside- and cholesterol-binding domains.

Fantini J, Yahi N. Adv Exp Med Biol. 2013;991:15-26. 

 

182. Cholesterol accelerates the binding of Alzheimer's β-amyloid peptide to ganglioside GM1 through a universal hydrogen-bond-dependent sterol tuning of glycolipid conformation.

Fantini J, Yahi N, Garmy N. Front Physiol. 2013 Jun 10;4:120.

 

181. Biochemical identification of a linear cholesterol-binding domain within Alzheimer's β amyloid peptide.

Di Scala C, Yahi N, Lelièvre C, Garmy N, Chahinian H, Fantini J. ACS Chem Neurosci. 2013 Mar 20;4(3):509-17.

 

180. How cholesterol interacts with membrane proteins: an exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains.

Fantini J, Barrantes FJ. Front Physiol. 2013 Feb 28;4:31. 

 

179. Sphingolipid-binding domain in the serotonin(1A) receptor.

Chattopadhyay A, Paila YD, Shrivastava S, Tiwari S, Singh P, Fantini J. Adv Exp Med Biol. 2012;749:279-93. 

 

178. Selective transmigration of monocyte-associated HIV-1 across a human cervical monolayer and its modulation by seminal plasma.

Lawrence P, Portran D, Terrasse R, Palle S, Olivier T, Fantini J, Bourlet T, Pozzetto B, Delezay O. AIDS. 2012 Apr 24;26(7):785-96.

 

177. A synthetic amino acid substitution of Tyr10 in Aβ peptide sequence yields a dominant negative variant in amyloidogenesis.

Mazargui H, Lévêque C, Bartnik D, Fantini J, Gouget T, Melone MA, Funke SA, Willbold D, Perrone L. Aging Cell. 2012 Jun;11(3):530-41. 

 

176. Disclosure of cholesterol recognition motifs in transmembrane domains of the human nicotinic acetylcholine receptor.

Baier CJ, Fantini J, Barrantes FJ. Sci Rep. 2011;1:69.

 

175. Synthesis, gp120 binding and anti-HIV activity of fatty acid esters of 1,1-linked disaccharides.

Bachan S, Fantini J, Joshi A, Garg H, Mootoo DR. Bioorg Med Chem. 2011 Aug 15;19(16):4803-11.

 

174. The fusogenic tilted peptide (67-78) of α-synuclein is a cholesterol binding domain.

Fantini J, Carlus D, Yahi N. Biochim Biophys Acta. 2011 Oct;1808(10):2343-51.

 

173. Molecular basis for the glycosphingolipid-binding specificity of α-synuclein: key role of tyrosine 39 in membrane insertion.

Fantini J, Yahi N. J Mol Biol. 2011 May 13;408(4):654-69.

 

172. Aβ behavior on neuronal membranes: aggregation and toxicities.

Yanagisawa K, Fantini J, Chakrabartty A, Eckert A. Int J Alzheimers Dis. 2011;2011:286536.

 

171.Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases.

Fantini J, Yahi N. Expert Rev Mol Med. 2010 Sep 1;12:e27. 

 

170. Non-lipolytic and lipolytic sequence-related carboxylesterases: a comparative study of the structure-function relationships of rabbit liver esterase 1 and bovine pancreatic bile-salt-activated lipase.

Chahinian H, Fantini J, Garmy N, Manco G, Sarda L. Biochim Biophys Acta. 2010 Nov;1801(11):1195-204. 

 

169. Some food-associated mycotoxins as potential risk factors in humans predisposed to chronic intestinal inflammatory diseases.

Maresca M, Fantini J. Toxicon. 2010 Sep 1;56(3):282-94. 

 

168. Mapping of domains on HIV envelope protein mediating association with calnexin and protein-disulfide isomerase.

Papandréou MJ, Barbouche R, Guieu R, Rivera S, Fantini J, Khrestchatisky M, Jones IM, Fenouillet E. J Biol Chem. 2010 Apr 30;285(18):13788-96. 

 

167. Notch ligand activity is modulated by glycosphingolipid membrane composition in Drosophila melanogaster.

Hamel S, Fantini J, Schweisguth F. J Cell Biol. 2010 Feb 22;188(4):581-94.

 

166. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.

Di Pasquale E, Fantini J, Chahinian H, Maresca M, Taïeb N, Yahi N. J Mol Biol. 2010 Mar 19;397(1):202-18.

 

165. How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's beta amyloid peptide (Abeta1-40).

Yahi N, Aulas A, Fantini J. PLoS One. 2010 Feb 5;5(2):e9079. 

 

164. Biophysical studies of the interaction of squalamine and other cationic amphiphilic molecules with bacterial and eukaryotic membranes: importance of the distribution coefficient in membrane selectivity.

Di Pasquale E, Salmi-Smail C, Brunel JM, Sanchez P, Fantini J, Maresca M. Chem Phys Lipids. 2010 Feb;163(2):131-40.

 

163. Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function.

Fantini J, Barrantes FJ. Biophys Acta. 2009 Nov;1788(11):2345-61. 

  

162. The insertion and transport of anandamide in synthetic lipid membranes are both cholesterol-dependent.

Di Pasquale E, Chahinian H, Sanchez P, Fantini J. PLoS One. 2009;4(3):e4989. 

 

161. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif.

Taïeb N, Maresca M, Guo XJ, Garmy N, Fantini J, Yahi N. Cancer Lett. 2009 Jun 18;278(2):164-73.

 

160. Squalamine: an appropriate strategy against the emergence of multidrug resistant gram-negative bacteria?

Salmi C, Loncle C, Vidal N, Letourneux Y, Fantini J, Maresca M, Taïeb N, Pagès JM, Brunel JM. PLoS One. 2008 Jul 23;3(7):e2765.

 

159. The extracellular glycosphingolipid-binding motif of Fas defines its internalization route, mode and outcome of signals upon activation by ligand.

Chakrabandhu K, Huault S, Garmy N, Fantini J, Stebe E, Mailfert S, Marguet D, Hueber AO. Cell Death Differ. 2008 Dec;15(12):1824-37.

 

158. Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry.

Garg H, Francella N, Tony KA, Augustine LA, Barchi JJ Jr, Fantini J, Puri A, Mootoo DR, Blumenthal R. Antiviral Res. 2008 Oct;80(1):54-61. 

 

157. Controlled aggregation of adenine by sugars: physicochemical studies, molecular modelling simulations of sugar-aromatic CH-pi stacking interactions, and biological significance.

Maresca M, Derghal A, Caravagna C, Dudin S, Fantini J. Phys Chem Chem Phys. 2008 May 21;10(19):2792-800.

 

156. Both direct and indirect effects account for the pro-inflammatory activity of enteropathogenic mycotoxins on the human intestinal epithelium: stimulation of interleukin-8 secretion, potentiation of interleukin-1beta effect and increase in the transepithelial passage of commensal bacteria.

Maresca M, Yahi N, Younès-Sakr L, Boyron M, Caporiccio B, Fantini J. Toxicol Appl Pharmacol. 2008 Apr 1;228(1):84-92.

 

155. Intestinal absorption of the acetamiprid neonicotinoid by Caco-2 cells: transepithelial transport, cellular uptake and efflux.

Brunet JL, Maresca M, Fantini J, Belzunces LP. J Environ Sci Health B. 2008 Mar-Apr;43(3):261-70.

 

154. Interaction of proteins with lipid rafts through glycolipid-binding domains: biochemical background and potential therapeutic applications.

Fantini J. Curr Med Chem. 2007;14(27):2911-7. 

 

153. Selective transport of staphylococcal enterotoxin A through in vitro generated human M cells.

Maresca M, Dumay E, Fantini J, Caporiccio B. Microbes Infect. 2007 Oct;9(12-13):1507-10.

 

152. The minimal amyloid-forming fragment of the islet amyloid polypeptide is a glycolipid-binding domain.

Levy M, Garmy N, Gazit E, Fantini J. FEBS J. 2006 Dec;273(24):5724-35.

 

151. Prediction of glycolipid-binding domains from the amino acid sequence of lipid raft-associated proteins: application to HpaA, a protein involved in the adhesion of Helicobacter pylori to gastrointestinal cells.

Fantini J, Garmy N, Yahi N. Biochemistry. 2006 Sep 12;45(36):10957-62.

 

150.Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor.

Boisseau S, Mabrouk K, Ram N, Garmy N, Collin V, Tadmouri A, Mikati M, Sabatier JM, Ronjat M, Fantini J, De Waard M. Biochim Biophys Acta. 2006 Mar;1758(3):308-19.

 

149. Cellular isoform of the prion protein PrPc in human intestinal cell lines: genetic polymorphism at codon 129, mRNA quantification and protein detection in lipid rafts.

Garmy N, Guo XJ, Taïeb N, Tourrès C, Tamalet C, Fantini J, Yahi N. Cell Biol Int. 2006 Jun;30(6):559-67. 

 

148. A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection.

Lund N, Branch DR, Mylvaganam M, Chark D, Ma XZ, Sakac D, Binnington B, Fantini J, Puri A, Blumenthal R, Lingwood CA. AIDS. 2006 Feb 14;20(3):333-43.

 

147. C-Glycoside analogues of beta-galactosylceramide with a simple ceramide substitute: synthesis and binding to HIV-1 gp120.

Augustin LA, Fantini J, Mootoo DR. Bioorg Med Chem. 2006 Feb 15;14(4):1182-8. 

 

146. Structural analysis of reverse transcriptase mutations at codon 215 explains the predominance of T215Y over T215F in HIV-1 variants selected under antiretroviral therapy.

Yahi N, Fantini J, Henry M, Tourrès C, Tamalet C. J Biomed Sci. 2005 Oct;12(5):701-10.

 

145. Apical uptake and transepithelial transport of sphingosine monomers through intact human intestinal epithelial cells: physicochemical and molecular modeling studies.

Garmy N, Taïeb N, Yahi N, Fantini J. Arch Biochem Biophys. 2005 Aug 1;440(1):91-100.

 

144. Interaction of cholesterol with sphingosine: physicochemical characterization and impact on intestinal absorption.

Garmy N, Taïeb N, Yahi N, Fantini J. J Lipid Res. 2005 Jan;46(1):36-45.

 

143. The combinatorial extension method reveals a sphingolipid binding domain on pancreatic bile salt-dependent lipase: role in secretion.

Aubert-Jousset E, Garmy N, Sbarra V, Fantini J, Sadoulet MO, Lombardo D. Structure. 2004 Aug;12(8):1437-47.

 

142. Human intestinal absorption of imidacloprid with Caco-2 cells as enterocyte model.

Brunet JL, Maresca M, Fantini J, Belzunces LP. Toxicol Appl Pharmacol. 2004 Jan 1;194(1):1-9.

 

141. Rafts and related glycosphingolipid-enriched microdomains in the intestinal epithelium: bacterial targets linked to nutrient absorption.

Taïeb N, Yahi N, Fantini J. Adv Drug Deliv Rev. 2004 Apr 19;56(6):779-94.

 

140. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes.

Tamalet C, Fantini J, Tourres C, Yahi N. AIDS. 2003 Nov 7;17(16):2383-8.

 

139. How sphingolipids bind and shape proteins: molecular basis of lipid-protein interactions in lipid shells, rafts and related biomembrane domains.

Fantini J. Cell Mol Life Sci. 2003 Jun;60(6):1027-32. 

 

138. The virotoxin model of HIV-1 enteropathy: involvement of GPR15/Bob and galactosylceramide in the cytopathic effects induced by HIV-1 gp120 in the HT-29-D4 intestinal cell line.

Maresca M, Mahfoud R, Garmy N, Kotler DP, Fantini J, Clayton F. J Biomed Sci. 2003 Jan-Feb;10(1):156-66.

 

137. Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases.

Fantini J, Garmy N, Mahfoud R, Yahi N. Expert Rev Mol Med. 2002 Dec 20;4(27):1-22.

 

136. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.

Nehete PN, Vela EM, Hossain MM, Sarkar AK, Yahi N, Fantini J, Sastry KJ. Antiviral Res. 2002 Dec;56(3):233-51.

 

135. A novel soluble analog of the HIV-1 fusion cofactor, globotriaosylceramide (Gb(3)), eliminates the cholesterol requirement for high affinity gp120/Gb(3) interaction.

Mahfoud R, Mylvaganam M, Lingwood CA, Fantini J. J Lipid Res. 2002 Oct;43(10):1670-9.

 

134. Asymmetric synthesis of water-soluble analogues of galactosylceramide, an HIV-1 receptor: new tools to study virus-glycolipid interactions.

Villard R, Hammache D, Delapierre G, Fotiadu F, Buono G, Fantini J. Chembiochem. 2002 Jun 3;3(6):517-25.

 

133.The mycotoxin deoxynivalenol affects nutrient absorption in human intestinal epithelial cells.

Maresca M, Mahfoud R, Garmy N, Fantini J. J Nutr. 2002 Sep;132(9):2723-31.

 

132. The mycotoxin patulin alters the barrier function of the intestinal epithelium: mechanism of action of the toxin and protective effects of glutathione.

Mahfoud R, Maresca M, Garmy N, Fantini J. Toxicol Appl Pharmacol. 2002 Jun 15;181(3):209-18.

 

131. J. Fantini, N. Garmy & N. Yahi (2002). Radeaux membranaires : le défi théapeutique. Biofutur, 219: 53.

 

130. Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins.

Mahfoud R, Garmy N, Maresca M, Yahi N, Puigserver A, Fantini J. J Biol Chem. 2002 Mar 29;277(13):11292-6. 

 

129. pH-dependent interaction of fumonisin B1 with cholesterol: physicochemical and molecular modeling studies at the air-water interface.

Mahfoud R, Maresca M, Santelli M, Pfohl-Leszkowicz A, Puigserver A, Fantini J. J Agric Food Chem. 2002 Jan 16;50(2):327-31.

 

128. Comparison of two commercial assays for the detection of insertion mutations of HIV-1 reverse transcriptase.

Koch N, Tamalet C, Tivoli N, Fantini J, Yahi N. J Clin Virol. 2001 May;21(2):153-62.

 

127. Characterization of galactosyl glycerolipids in the HT29 human colon carcinoma cell line.

Påhlsson P, Spitalnik SL, Spitalnik PF, Fantini J, Rakotonirainy O, Ghardashkhani S, Lindberg J, Konradsson P, Larson G. Arch Biochem Biophys. 2001 Dec 15;396(2):187-98.

 

126. The mycotoxin ochratoxin A alters intestinal barrier and absorption functions but has no effect on chloride secretion.

Maresca M, Mahfoud R, Pfohl-Leszkowicz A, Fantini J.

Toxicol Appl Pharmacol. 2001 Oct 1;176(1):54-63.

 

125. Gp120-induced Bob/GPR15 activation: a possible cause of human immunodeficiency virus enteropathy.

Clayton F, Kotler DP, Kuwada SK, Morgan T, Stepan C, Kuang J, Le J, Fantini J. Am J Pathol. 2001 Nov;159(5):1933-9. 

 

124. Amphiphilic anionic analogues of galactosylceramide: synthesis, anti-HIV-1 activity, and gp120 binding.

Faroux-Corlay B, Greiner J, Terreux R, Cabrol-Bass D, Aubertin AM, Vierling P, Fantini J. J Med Chem. 2001 Jun 21;44(13):2188-203.

 

123. Secondary structure predictions of HIV-1 reverse transcriptase provide new insights into the development of drug-resistance genotypes.

Fantini J, Tamalet C, Yahi N. AIDS. 2001 Jun 15;15(9):1191-2. 

 

122. Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale.

Yahi N, Fantini J, Tourres C, Tivoli N, Koch N, Tamalet C. J Infect Dis. 2001 May 1;183(9):1311-7. 

 

121. Genetic analysis of hiv type 1 strains in bujumbura (burundi): predominance of subtype c variant.

Koch N, Ndihokubwayo JB, Yahi N, Tourres C, Fantini J, Tamalet C. AIDS Res Hum Retroviruses. 2001 Feb 10;17(3):269-73.

 

120. Mutations in HIV-1 gag cleavage sites and their association with protease mutations.

Koch N, Yahi N, Fantini J, Tamalet C. AIDS. 2001 Mar 9;15(4):526-8.

 

119. Total synthesis of mololipids: a new series of anti-HIV Moloka'iamine derivatives.

Schoenfeld RC, Lumb JP, Fantini J, Ganem B. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2679-81.

 

118. Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion.

Fantini J, Hammache D, Piéroni G, Yahi N. Glycoconj J. 2000 Mar-Apr;17(3 -4):199-204.

 

117. Glycosphingolipid (GSL) microdomains as attachment platforms for host pathogens and their toxins on intestinal epithelial cells: activation of signal transduction pathways and perturbations of intestinal absorption and secretion.

Fantini J, Maresca M, Hammache D, Yahi N, Delézay O. Glycoconj J. 2000 Mar-Apr;17(3 -4):173-9.

 

116. Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase.

Yahi N, Tamalet C, Tourrès C, Tivoli N, Fantini J. J Biomed Sci. 2000 Nov-Dec;7(6):507-13.

 

115. D. Hammache, N. Yahi & J. Fantini (2000). Microdomaines membranaires et infection virale: implication des glycosphingolipides dans la fusion du VIH-1 avec la membrane plasmique des cellules cibles. Oléagineux, Corps Gras et Lipides, 7: 449-455. (print copy available upon request)

 

114. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations.

Tamalet C, Yahi N, Tourrès C, Colson P, Quinson AM, Poizot-Martin I, Dhiver C, Fantini J. Virology. 2000 May 10;270(2):310-6.

 

113. Synthesis of glycolipid analogues that disrupt binding of HIV-1 gp120 to galactosylceramide.

Weber KT, Hammache D, Fantini J, Ganem B. Bioorg Med Chem Lett. 2000 May 15;10(10):1011-4.

 

112. Synthesis of single- and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activity.

Faroux-Corlay B, Clary L, Gadras C, Hammache D, Greiner J, Santaella C, Aubertin AM, Vierling P, Fantini J. Carbohydr Res. 2000 Jul 24;327(3):223-60.

 

111. Reconstitution of sphingolipid-cholesterol plasma membrane microdomains for studies of virus-glycolipid interactions.

Hammache D, Piéroni G, Maresca M, Ivaldi S, Yahi N, Fantini J. Methods Enzymol. 2000;312:495-506.

 

110. Synthetic soluble analogs of glycolipids for studies of virus-glycolipid interactions.

Fantini J. Methods Enzymol. 2000;311:626-38.

 

109. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences.

Yahi N, Tamalet C, Tourrès C, Tivoli N, Ariasi F, Volot F, Gastaut JA, Gallais H, Moreau J, Fantini J. J Clin Microbiol. 1999 Dec;37(12):4099-106.

 

108. C. Tamalet, N. Yahi, J. Fantini & H. Gallais (1999). Evolution des populations virales analysées par séquençage du gène pol après institution d’une trithérapie au moment de la primo-infection à VIH. Virologie, 3: 247-248.

 

107. N. Yahi, C. Tamalet & J. Fantini (1999). Genetic rearrangements (insertions, deletions, recombinations and mutations) in HIV-1 reverse transcriptase and protease genes during antiretroviral combination therapy: biochemical background and clinical significance. Recent Res. Develop. Biochem, 1: 77-88. (print copy available upon request)

 

106. Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3).

Hammache D, Yahi N, Maresca M, Piéroni G, Fantini J. J Virol. 1999 Jun;73(6):5244-8.

 

105. Genetic polymorphism near HIV-1 reverse transcriptase resistance-associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis.

Koch N, Yahi N, Colson P, Fantini J, Tamalet C. J Virol Methods. 1999 Jun;80(1):25-31.

 

104. Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy.

Koch N, Yahi N, Ariasi F, Fantini J, Tamalet C. J Clin Microbiol. 1999 May;37(5):1595-7.

 

103. Glycolipids as potential binding sites for HIV: topology in the sperm plasma membrane in relation to the regulation of membrane fusion.

Gadella BM, Hammache D, Piéroni G, Colenbrander B, van Golde LM, Fantini J. J Reprod Immunol. 1998 Dec;41(1-2):233-53.

 

102. D. Hammache, N. Yahi & J. Fantini (1998). L’interaction du virus de l’immunodéficience humaine (VIH) avec ses récepteurs glycolipidiques. Regard sur la Biochimie, 4: 22-31.

 

101. HIV-1-induced perturbations of glycosphingolipid metabolism are cell-specific and can be detected at early stages of HIV-1 infection.

Fantini J, Tamalet C, Hammache D, Tourrès C, Duclos N, Yahi N. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1;19(3):221-9.

 

100. Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy.

Tamalet C, Izopet J, Koch N, Fantini J, Yahi N. AIDS. 1998 Oct 1;12(14):F161-6.

 

99. Sulfatide inhibits HIV-1 entry into CD4-/CXCR4+ cells.

Fantini J, Hammache D, Delézay O, Piéroni G, Tamalet C, Yahi N. Virology. 1998 Jul 5;246(2):211-20.

 

98. Sequential interaction of CD4 and HIV-1 gp120 with a reconstituted membrane patch of ganglioside GM3: implications for the role of glycolipids as potential HIV-1 fusion cofactors.

Hammache D, Yahi N, Piéroni G, Ariasi F, Tamalet C, Fantini J. Biochem Biophys Res Commun. 1998 May 8;246(1):117-22.

 

97. Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3.

Hammache D, Piéroni G, Yahi N, Delézay O, Koch N, Lafont H, Tamalet C, Fantini J. J Biol Chem. 1998 Apr 3;273(14):7967-71.

 

96. Direct effect of type 1 human immunodeficiency virus (HIV-1) on intestinal epithelial cell differentiation: relationship to HIV-1 enteropathy.

Delézay O, Yahi N, Tamalet C, Baghdiguian S, Boudier JA, Fantini J. Virology. 1997 Nov 24;238(2):231-42.

 

95. HIV-1 transmission across the vaginal epithelium.

Fantini J, Yahi N, Tourres C, Delézay O, Tamalet C. AIDS. 1997 Nov;11(13):1663-4.

 

94. Co-expression of CXCR4/fusin and galactosylceramide in the human intestinal epithelial cell line HT-29.

Delézay O, Koch N, Yahi N, Hammache D, Tourres C, Tamalet C, Fantini J. AIDS. 1997 Sep;11(11):1311-8.

 

93. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.

Tamalet C, Lafeuillade A, Fantini J, Poggi C, Yahi N. AIDS. 1997 Jun;11(7):895-901.

 

92. Perturbations of glucose metabolism associated with HIV infection in human intestinal epithelial cells: a multinuclear magnetic resonance spectroscopy study.

Lutz NW, Yahi N, Fantini J, Cozzone PJ. AIDS. 1997 Feb;11(2):147-55.

 

91. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry.

Fantini J, Hammache D, Delézay O, Yahi N, André-Barrès C, Rico-Lattes I, Lattes A. J Biol Chem. 1997 Mar 14;272(11):7245-52.

 

90. S. Baghdiguian & J. Fantini (1997). Suramin: a molecule with a road spectrum of biological and therapeutic properties. Cancer J., 10: 31-37. (print copy available upon request)

 

89. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.

Delézay O, Hammache D, Fantini J, Yahi N. Biochemistry. 1996 Dec 10;35(49):15663-71.

 

88. J. Fantini, N. Yahi, K. Mabrouk,H. Rochat, J. Van Rietschoten & J.M. Sabatier (1996). V3 loop-derived multibranched peptides as inhibitors of HIV infection in CD4+ and CD4- cells. Persp. Drug. Discov. Des., 5: 243-250.

 

87. D. Hammache, O. Delézay, J. Fantini, & N. Yahi  (1996). Suramin: a polysulfonated compound that inhibits the binding of HIV-1 gp120 to GalCer/sulfatide and blocks the CD4-independent pathway of HIV-1 infection in mucosal epithelial cells. Persp. Drug. Discov. Des., 5: 225-233.

 

86. O. Delézay, N. Yahi, N & J. Fantini (1996). Detection of functional galactosylceramide (GalCer) receptors on CD4-negative target cells. Persp. Drug. Discov. Des., 5: 192-202.

 

85. G. Dayanithi, N. Yahi, S. Baghdiguian & J. Fantini (1996). Galactosylceramide and transmembrane signalling in enterocytes: calcium response induced by HIV-1 surface envelope glycoprotein gp120. Persp. Drug. Discov. Des., 5: 181-191.

 

84. N. Yahi, L. Ratner, J.M. Harouse, F. Gonzalez-Scarano & J. Fantini (1996). Genetic determinants controlling HIV-1 tropism for CD4-/GalCer+ human intestinal epithelial cells. Persp. Drug. Discov. Des., 5: 161-168.

 

83. S. Baghdiguian, N. Yahi & J. Fantini (1996). Morphological alterations associated with HIV infection of CD4-/GalCer+ human intestinal epithelial cells. Persp. Drug. Discov. Des., 5: 73-82.

 

82. J. Fantini & J.M. Sabatier (1996). HIV infection in CD4- cells. Preface.   Persp. Drug. Discov. Des., 5: V-VI.

 

81. Analysis of individual purine and pyrimidine nucleoside di- and triphosphates and other cellular metabolites in PCA extracts by using multinuclear high resolution NMR spectroscopy.

Lutz NW, Yahi N, Fantini J, Cozzone PJ. Magn Reson Med. 1996 Nov;36(5):788-95.

 

80. A new method for the determination of specific 13C enrichment in phosphorylated [1-13C]glucose metabolites. 13C-coupled, 1H-decoupled 31P-NMR spectroscopy of tissue perchloric acid extracts.

Lutz NW, Yahi N, Fantini J, Cozzone PJ. Eur J Biochem. 1996 Jun 1;238(2):470-5.

 

79. Co-localization of suramin and serum albumin in lysosomes of suramin-treated human colon cancer cells.

Baghdiguian S, Boudier JA, Boudier JL, Fantini J. Cancer Lett. 1996 Mar 29;101(2):179-84.

 

78.Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography.

Baghdiguian S, Boudier JL, Boudier JA, Fantini J. Eur J Cancer. 1996 Mar;32A(3):525-32.

 

77. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.

Yahi N, Fantini J, Baghdiguian S, Mabrouk K, Tamalet C, Rochat H, Van Rietschoten J, Sabatier JM. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4867-71.

 

76. Intracellular calcium release induced by human immunodeficiency virus type 1 (HIV-1) surface envelope glycoprotein in human intestinal epithelial cells: a putative mechanism for HIV-1 enteropathy.

Dayanithi G, Yahi N, Baghdiguian S, Fantini J. Cell Calcium. 1995 Jul;18(1):9-18.

 

75.SPC3, a nontoxic peptide inhibitor of HIV infection.

Sabatier JM, Baghdiguian S, Yahi N, Rochat H, Van Rietschoten J, Fantini J. In Vitro Cell Dev Biol Anim. 1995 Jun;31(6):415-8. 

 

74. J. Fantini, S. Baghdiguian, J.M. Sabatier & N. Yahi (1995). Rôle des glycolipides dans l'infection des cellules par le virus du SIDA. Oléagineux, Corps Gras et Lipides, 2: 104-107. (print copy available upon request)

 

73. The development of Na(+)-dependent glucose transport during differentiation of an intestinal epithelial cell clone is regulated by protein kinase C.

Delézay O, Baghdiguian S, Fantini J. J Biol Chem. 1995 May 26;270(21):12536-41.

 

72. Characterization of an electrogenic sodium/glucose cotransporter in a human colon epithelial cell line.

Delezay O, Verrier B, Mabrouk K, van Rietschoten J, Fantini J, Mauchamp J, Gerard C. J Cell Physiol. 1995 Apr;163(1):120-8.

 

71. Production of a highly cytopathic HIV-1 isolate from a human mucosal epithelial cell line cultured on microcarrier beads in serum-free medium.

Yahi N, Baghdiguian S, Fantini J. In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):62-6.

 

70. Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.

Yahi N, Sabatier JM, Baghdiguian S, Gonzalez-Scarano F, Fantini J. J Virol. 1995 Jan;69(1):320-5.

 

69. J. Fantini, N. Yahi, K. Mabrouk, J. Van Rietschoten, H. Rochat & J.M. Sabatier (1994). Multibranched V3 peptides as HIV inhibitors.  Curr.Topics Peptide Prot. Res., 1: 11-24.

 

68. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells.

Yahi N, Sabatier JM, Nickel P, Mabrouk K, Gonzalez-Scarano F, Fantini J. J Biol Chem. 1994 Sep 30;269(39):24349-53.

 

67.Interferon-gamma decreases cell surface expression of galactosyl ceramide, the receptor for HIV-1 GP120 on human colonic epithelial cells.

Yahi N, Spitalnik SL, Stefano KA, De Micco P, Gonzalez-Scarano F, Fantini J. Virology. 1994 Nov 1;204(2):550-7.

 

66. Physical contact with lymphocytes is required for reactivation of dormant HIV-1 in colonic epithelial cells: involvement of the HIV-1 LTR.

Faure E, Yahi N, Zider A, Cavard C, Champion S, Fantini J. Virus Res. 1994 Oct;34(1):1-13.

 

65. Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.

Yahi N, Fantini J, Mabrouk K, Tamalet C, de Micco P, van Rietschoten J, Rochat H, Sabatier JM. J Virol. 1994 Sep;68(9):5714-20.

 

64. J. Fantini, N. Yahi, K. Mabrouk, J. Van Rietschoten, H. Rochat & J.M. Sabatier (1994). Evaluation of multibranched V3 peptides as inhibitors of HIV infection.  Lett. Peptide Sci., 1: 17-24

 

63. Binding of human immunodeficiency virus type I (HIV-1) gp120 to galactosylceramide (GalCer): relationship to the V3 loop.

Cook DG, Fantini J, Spitalnik SL, Gonzalez-Scarano F. Virology. 1994 Jun;201(2):206-14.

 

62. GalCer, CD26 and HIV infection of intestinal epithelial cells.

Fantini J, Yahi N, Delezay O, Gonzalez-Scarano F. AIDS. 1994 Sep;8(9):1347-8. 

 

61. J. Fantini, N. Yahi, S. Baghdiguian, S.L. Spitalnik & F. Gonzalez-Scarano (1994). HIV infection of human intestinal epithelial cells. Mucosal Immunol. Update, 2: 1-13. (print copy available upon request)

 

60. J. Fantini, N. Yahi, K. Mabrouk, J. Van Rietschoten, H. Rochat & J.M. Sabatier (1994). Des constructions peptidiques (SPC) inhibent l'entrée du VIH dans les cellules: une nouvelle classe d'anti-rétroviraux. Science Technique Technologie, 26: 4-8. (print copy available upon request)

 

59. D.G. Cook, J. Fantini, S.L. Spitalnik & F. Gonzalez-Scarano (1994). Application of high performance thin layer chromatography (HPTLC) to investigate interactions between HIV-1 glycoprotein gp120 and galactosyl ceramide (GalCer).  Meth. Molec. Genetics, 4: 86-92. (print copy available upon request)

 

58. Autoradiographic localization of tritiated suramin in polarized human colon adenocarcinoma cells.

Baghdiguian S, Boudier JA, Boudier JL, Fantini J. Cancer Lett. 1993 Dec 20;75(3):151-6.

 

57.Multi-branched peptides based on the HIV-1 V3 loop consensus motif inhibit HIV-1 and HIV-2 infection in CD4+ and CD4- cells.

Fantini J, Yahi N, Mabrouk K, Van Rietschoten J, Rochat H, Sabatier JM. C R Acad Sci III. 1993 Nov;316(11):1381-7.

 

56. J. Fantini & N. Yahi (1993). Le galactosyl céramide: un nouveau récepteur pour le virus de l'immunodéficience humaine.  Médecine & Sciences, 9: 891-900. 

 

55. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor.

Fantini J, Cook DG, Nathanson N, Spitalnik SL, Gonzalez-Scarano F. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2700-4.

 

54. Polarized distribution of gamma interferon-stimulated MHC antigens and transferrin receptors in a clonal cell line isolated from Fisher rat thyroid (FRT cells).

Boudier JA, Fantini J, Gerard C, Verrier B. Cell Tissue Res. 1993 Apr;272(1):23-31.

 

53. Special lectures VIII. AIDS.

Chermann JC, Fantini J, Calenda V, Silvy F, Hirsch I. AIDS Res Hum Retroviruses. 1992 May;8(5):711-8. 

 

52. Tumor necrosis factor-alpha stimulates both apical and basal production of HIV in polarized human intestinal HT29 cells.

Fantini J, Bolmont C, Yahi N. Immunol Lett. 1992 Sep;34(1):85-90.

 

51. Replication and apical budding of HIV-1 in mucous-secreting colonic epithelial cells.

Yahi N, Baghdiguian S, Bolmont C, Fantini J. J Acquir Immune Defic Syndr. 1992 Oct;5(10):993-1000.

 

50.Inhibition of human immunodeficiency virus infection in human colon epithelial cells by recombinant interferon-gamma.

Yahi N, Baghdiguian S, Bolmont C, Fantini J. Eur J Immunol. 1992 Oct;22(10):2495-9.

 

49. Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT29 cells.

Yahi N, Baghdiguian S, Moreau H, Fantini J. J Virol. 1992 Aug;66(8):4848-54.

 

48. J. Fantini (1992). Differentiation in human colic tumor cells: importance of autocrine growth factors. Cancer J., 5: 78-83. (print copy available upon request)

 

47. J. Fantini (1992). Epithélium intestinal et VIH.  Médecine & Sciences, 8: 178-179.

 

46. Energetic metabolism of glucose, mannose and galactose in glucose-starved rat insulinoma cells anchored on microcarrier beads. A phosphorus-31 NMR study.

Kriat M, Fantini J, Vion-Dury J, Confort-Gouny S, Galons JP, Cozzone PJ. Biochimie. 1992 Sep-Oct;74(9-10):949-55.

 

45. Suramin induces lysosomal storage disorder in HT29-D4 cells during a mechanism of polarized endocytosis.

Baghdiguian S, Boudier JA, Verrier B, Zappitelli JP, Fantini J. C R Acad Sci III. 1992;314(2):67-73. French.

 

44.  Infection of HIV-1 and HIV-2 through the luminal and serosal sides of polarized human intestinal epithelial cells.

Yahi N, Fantini J, Chermann JC. AIDS. 1992 Mar;6(3):335-6. 

 

43. Structural variability of env and gag gene products from a highly cytopathic strain of HIV-1.

Yahi N, Fantini J, Hirsch I, Chermann JC. Arch Virol. 1992;125(1-4):287-98.

 

42. Insulin like growth factor I is an autocrine regulator of human colon cancer cell differentiation and growth.

Baghdiguian S, Verrier B, Gerard C, Fantini J. Cancer Lett. 1992 Feb 14;62(1):23-33.

 

41.  Short-term suramin treatment followed by the removal of the drug induces terminal differentiation of HT29-D4 cells.

Baghdiguian S, Verrier B, Marvaldi J, Fantini J. J Cell Physiol. 1992 Jan;150(1):168-74.

 

40. Human colon epithelial cells productively infected with human immunodeficiency virus show impaired differentiation and altered secretion.

Fantini J, Yahi N, Baghdiguian S, Chermann JC. J Virol. 1992 Jan;66(1):580-5.

 

39.Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines.

Bellan C, Pic P, Marvaldi J, Fantini J, Pichon J. Second Messengers Phosphoproteins. 1991;13(4):163-71.

 

38. J.C. Chermann, V. Calenda, J. Fantini & I. Hirsch (1991). Le virus HIV: sa variabilité et son rôle dans le SIDA et les maladies associées. Science Technique Technologie, 19: 4-10. (print copy available upon request)

 

37. Selected human immunodeficiency virus replicates preferentially through the basolateral surface of differentiated human colon epithelial cells.

Fantini J, Baghdiguian S, Yahi N, Chermann JC. Virology. 1991 Dec;185(2):904-7.

 

36. Double screening of suramin derivatives on human colon cancer cells and on neural cells provides new therapeutic agents with reduced toxicity.

Baghdiguian S, Nickel P, Fantini J. Cancer Lett. 1991 Dec 1;60(3):213-9.

 

35. Human immunodeficiency virus can infect the apical and basolateral surfaces of human colonic epithelial cells.

Fantini J, Yahi N, Chermann JC. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9297-301.

 

34. Kinetics of biochemical, electrophysiological and morphological events (including lysosomal disorder) during the course of suramin-induced differentiation of the human colon-cancer cell clone HT29-D4.

Baghdiguian S, Verrier B, Marvaldi J, Fantini J. Int J Cancer. 1991 Oct 21;49(4):608-15.

 

33. Human T-lymphoblastoid cells selected for growth in serum-free medium provide new tools for study of HIV replication and cytopathogenicity.

Yahi N, Fantini J, Baghdiguian S, Chermann JC. J Virol Methods. 1991 Sep-Oct;34(2):193-207.

 

32. Suramin inhibits the proliferation and stimulates the differentiation of tumoral cell lines HT29-D4 and C6.

Baghdiguian S, Pichon J, Marvaldi J, Fantini J. Bull Cancer. 1991;78(9):807-17.

 

31. Vectorial release of carcinoembryonic antigen induced by IFN-gamma in human colon cancer cells cultured in serum-free medium.

Baghdiguian S, Verrier B, Roccabianca M, Pommier G, Marvaldi J, Fantini J. Eur J Cancer. 1991;27(5):599-604.

 

30. Combination of culture on collagen gels and glucose starvation for cloning human colon cancer cells. Obtention of clones exhibiting different patterns of enterocytic differentiation.

Lehmann M, Rabenandrasana C, Rognoni JB, Verrier B, Marvaldi J, Fantini J. Cytotechnology. 1991 Feb;5(2):117-27.

 

29. The in vitro differentiation of cancer cells of the human colon (HT29-D4) is associated with the presence of annulate lamellae in the basal part of the cytoplasm.

Baghdiguian S, Fantini J. C R Acad Sci III. 1990;311(10):347-52.

 

28. A suramin derivative induces enterocyte-like differentiation of human colon cancer cells without lysosomal storage disorder.

Baghdiguian S, Nickel P, Marvaldi J, Fantini J. Anticancer Drugs. 1990 Oct;1(1):59-66.

 

27. The concentration of glucose in the culture medium determines the effect of suramin on the growth and differentiation of the human colonic adenocarcinoma cell clone HT29-D4.

Rabenandrasana C, Baghdiguian S, Roccabianca M, Brunet M, Marvaldi J, Fantini J. Cancer Lett. 1990 Sep;53(2-3):109-15.

 

26.  Evaluation of the effect of suramin on neural cell growth and N-CAM expression.

Guo XJ, Fantini J, Roubin R, Marvaldi J, Rougon G. Cancer Res. 1990 Aug 15;50(16):5164-70.

 

25. CD4 molecules are restricted to the basolateral membrane domain of in vitro differentiated human colon cancer cells (HT29-D4).

Rabenandrasana C, Baghdiguian S, Marvaldi J, Fantini J. FEBS Lett. 1990 Jun 4;265(1-2):75-9.

 

24. Suramin-induced differentiation of the human colic adenocarcinoma cell clone HT29-D4 in serum-free medium.

Fantini J, Verrier B, Robert C, Pic P, Pichon J, Mauchamp J, Marvaldi J. Exp Cell Res. 1990 Jul;189(1):109-17.

 

23. Production of insulin-like growth factor II (IGF-II) and different forms of IGF-binding proteins by HT-29 human colon carcinoma cell line.

Culouscou JM, Remacle-Bonnet M, Garrouste F, Fantini J, Marvaldi J, Pommier G. J Cell Physiol. 1990 Jun;143(3):405-15.

 

22. Impaired carcinoembryonic antigen release during the process of suramin-induced differentiation of the human colonic adenocarcinoma cell clone HT29-D4.

Fantini J, Rognoni JB, Theveniau M, Pommier G, Marvaldi J. J Cell Physiol. 1990 Jun;143(3):468-74.

 

21. Suramin inhibits proliferation of rat glioma cells and alters N-CAM cell surface expression.

Fantini J, Guo XJ, Marvaldi J, Rougon G. Int J Cancer. 1990 Mar 15;45(3):554-61.

 20. J. Fantini, J.B. Rognoni, M. Lehman, M. Roccabianca, G. Pommier, A. Tirard & J. Marvaldi (1990). La différenciation in vitro d'un clone de cellules d'adénocarcinome colique humain (HT29-D4) peut être induite en carence de glucose ou en présence de suramine. Revue Française des Laboratoires, 208: 54-62. (print copy available upon request)

 

19. Suramin-treated HT29-D4 cells grown in the presence of glucose in permeable culture chambers form electrically active epithelial monolayers. A comparative study with HT29-D4 cells grown in the absence of glucose.

Fantini J, Rognoni JB, Verrier B, Lehmann M, Roccabianca M, Mauchamp J, Marvaldi J. Eur J Cell Biol. 1990 Feb;51(1):110-9.

 

 18.Effect of VIP on the glycogen metabolism of human colon adenocarcinoma cells studied by 13C nuclear magnetic resonance spectroscopy.

Galons JP, Fantini J, Vion-Dury J, Cozzone PJ, Canioni P. Int J Cancer. 1990 Jan 15;45(1):168-73.

 

17. Metabolic changes in undifferentiated and differentiated human colon adenocarcinoma cells studied by multinuclear magnetic resonance spectroscopy.

Galons JP, Fantini J, Vion-Dury J, Cozzone PJ, Canioni P. Biochimie. 1989 Aug;71(8):949-61.

 

16.Induction of polarized apical expression and vectorial release of carcinoembryonic antigen (CEA) during the process of differentiation of HT29-D4 cells.

Fantini J, Rognoni JB, Culouscou JM, Pommier G, Marvaldi J, Tirard A. J Cell Physiol. 1989 Oct;141(1):126-34.

 

15. Phosphorus-31 nuclear magnetic resonance study of the C6 glioma cell line cultured on microcarrier beads.

Vion-Dury J, Galons JP, Fantini J, Confort-Gouny S, Kriat M, Cozzone PJ. Brain Res. 1989 Jul 24;493(1):175-8.

 

14. Suramin inhibits cell growth and glycolytic activity and triggers differentiation of human colic adenocarcinoma cell clone HT29-D4.

Fantini J, Rognoni JB, Roccabianca M, Pommier G, Marvaldi J. J Biol Chem. 1989 Jun 15;264(17):10282-6.

 

13. In vitro differentiated HT 29-D4 clonal cell line generates leakproof and electrically active monolayers when cultured in porous-bottom culture dishes.

Fantini J, Verrier B, Marvaldi J, Mauchamp J. Biol Cell. 1989;65(2):163-9.

 

12. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4). Fantini J, Martin JM, Luis J, Rémy L, Tirard A, Marvaldi J, Pichon J. Eur J Cell Biol. 1988 Aug;46(3):458-65.

 

11. A. El Battari, J. Luis, J.M. Martin, J. Fantini, J.M. Muller, J. Marvaldi & J. Pichon (1988). The glycoprotein nature of the vasoactive intestinal peptide (VIP) binding site. Role of carbohydrates in VIP binding on HT 29-D4 cells. Ann. N.Y. Acad Sci., 527: 667-671.

 

10. Evidence for an ectophosvitin kinase activity that phosphorylates a 123 kDa endogenous substrate on a human colonic adenocarcinoma cell (HT 29).

Fantini J, Muller JM, Abadie B, el Battari A, Marvaldi J, Tirard A. Eur J Cell Biol. 1987 Jun;43(3):342-7.

 

9. Cycloheximide induces accumulation of vasoactive intestinal peptide (VIP) binding sites at the cell surface of a human colonic adenocarcinoma cell line (HT29-D4). Evidence for the presence of an intracellular pool of VIP receptors.

Luis J, Martin JM, el Battari A, Fantini J, Giannellini F, Marvaldi J, Pichon J. Eur J Biochem. 1987 Sep 1;167(2):391-6.

 

8. Growth in serum-free medium of human colonic adenocarcinoma cell lines on microcarriers: a two-step method allowing optimal cell spreading and growth.

Fantini J, Galons JP, Abadie B, Canioni P, Cozzone PJ, Marvaldi J, Tirard A. In Vitro Cell Dev Biol. 1987 Sep;23(9):641-6.

 

7. Growth of a human colonic adenocarcinoma cell line (HT 29) on microcarrier beads: metabolic studies by 31phosphorus nuclear magnetic resonance spectroscopy.

Fantini J, Galons JP, Marvaldi J, Cozzone PJ, Canioni P. Int J Cancer. 1987 Feb 15;39(2):255-60.

 

6. The vasoactive intestinal peptide receptor on intact human colonic adenocarcinoma cells (HT29-D4). Evidence for its glycoprotein nature.

el Battari A, Luis J, Martin JM, Fantini J, Muller JM, Marvaldi J, Pichon J. Biochem J. 1987 Feb 15;242(1):185-91.

 

5.Spontaneous and induced dome formation by two clonal cell populations derived from a human adenocarcinoma cell line, HT29.

Fantini J, Abadie B, Tirard A, Remy L, Ripert JP, el Battari A, Marvaldi J. J Cell Sci. 1986 Jul;83:235-49.

 

4. Monensin and tunicamycin-induced inhibition of HT29 cell spreading and growth.

el-Battari A, Muller JM, Fantini J, Bellot F, Tirard A, Ducret F, Marvaldi J. J Cell Sci. 1986 Feb;80:269-80.

 

3. Characterization of the vasoactive intestinal peptide (VIP) binding sites: a biochemical and an immunological approach.

Marvaldi J, Luis J, Muller JM, el Battari A, Fantini J, Martin JM, Abadie B, Tirard A, Pichon J. Peptides. 1986;7 Suppl 1:137-45.

 

 2.  The intestinal immune system. The VIP receptor on T lymphocytes: a new marker of differentiation?.

Fantini J, Tirard A, el Battari A, Luis J, Muller JM, Pichon J, Marvaldi J. Gastroenterol Clin Biol. 1985 Dec;9(12):929-35. 

 

1.  Covalent cross-linking of vasoactive intestinal peptide (VIP) to its receptor in intact colonic adenocarcinoma cells in culture (HT 29).

Muller JM, Luis J, Fantini J, Abadie B, Giannellini F, Marvaldi J, Pichon J. Eur J Biochem. 1985 Sep 2;151(2):411-7.

 

 

 

Home * Research team * Main findings * List of Publications * Brain lipids textbook * Teaching * Students * Living in Marseille * Download * Laboratory page